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Abstract
 .The cytokine interleukin-1b IL-1b has been shown to inhibit insulin secretion and destroy pancreatic islets by a
 .  .mechanism that involves the expression of inducible nitric oxide synthase iNOS , and the production of nitric oxide NO .
Insulin containing b-cells, selectively destroyed during the development of autoimmune diabetes, appear to be the islet
cellular source of iNOS following treatment with IL-1b. In this study we have evaluated the presence of type I IL-1
 .signaling receptors on purified pancreatic b-cells. We show that the interleukin-1 receptor antagonist protein IRAP
prevents IL-1b-induced nitrite formation and IL-1b-induced inhibition of insulin secretion by isolated islets and primary
 .b-cells purified by fluorescence-activated cell sorting FACS . The protective effects of IRAP correlate with an inhibition of
IL-1b-induced iNOS expression by islets and FACS purified b-cells. To provide direct evidence to support b-cell
expression of IL-1 type I signaling receptors, we show that antiserum specific for the type I IL-1 receptor neutralizes
IL-1b-induced nitrite formation by RINm5F cells, and that RINm5F cells express the type I IL-1 receptor at the protein
 .level. Using reverse transcriptase-polymerase chain reaction RT-PCR , the expression of type I IL-1 signaling receptors by
FACS purified b-cells and not a-cells is demonstrated. These results provide direct support for the expression of type I
IL-1 receptors by primary pancreatic b-cells, the cell type selectively destroyed during the development of autoimmune
diabetes. q 1997 Elsevier Science B.V.
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1. Introduction
 .Insulin-dependent diabetes mellitus IDDM is
characterized by a local inflammatory reaction in and
around pancreatic islets, followed by selective de-
struction of insulin secreting b-cells. b-cell destruc-
tion has been proposed to involve cytokines released
from lymphocytes and macrophages during islet in-
flammation, and by T-cell specific mechanisms. The
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role of cytokines was first demonstrated by Nerup
w xand coworkers 1,2 who showed that treatment of rat
islets with IL-1b results in a potent inhibition of
insulin secretion and islet cell death. The inhibitory
effects of IL-1b on insulin secretion are both time-
w xand concentration-dependent 3,4 .
The mechanism by which IL-1b exerts its in-
hibitory actions on pancreatic islet b-cells is believed
w xto involve IL-1 binding to cell-surface receptors 5 ,
followed by signal transduction events leading to
w xgene activation and expression of iNOS 6 . iNOS
catalyzes the five electron oxidation of L-arginine to
L-citrulline and the production of the free radical NO
w x7,8 . The inhibitory effects of IL-1b on islet func-
tion are the result of NO-mediated destruction of
w xmitochondrial iron-sulfur centers of aconitase 9,10 ,
and possibly the electron transport chain at com-
w xplexes I and II 11,12 . Evidence for iron-sulfur cen-
ter destruction includes IL-1-induced iron-nitrosyl
w xcomplex formation by islets 10,12,13 and the inhibi-
tion of mitochondrial aconitase activity of rat islets
w xand the insulinoma cell line RINm5F 9,10 . In-
hibitors of iNOS, N G-monomethyl-L-arginine
 w x. GNMMA; 9,10 , N -nitro-L-arginine methyl ester
 w x.  w x.NAME; 14 , and aminoguanidine AG; 15 pre-
vent the inhibitory effects of IL-1b on islet function.
Alternative methods to prevent the cytotoxic ef-
fects of IL-1b on islet function include blocking IL-1
cell-surface receptor binding and therefore preventing
signal transduction events that ultimately lead to the
expression of iNOS. The interleukin-1 receptor antag-
 .onist protein IRAP is an endogenous species that
competes with IL-1 for binding to specific IL-1 re-
ceptors. In this fashion IRAP prevents signal trans-
w xduction events induced by IL-1 16,17 . IRAP has
been shown to prevent the inhibitory effects of IL-1b
on insulin secretion and glucose oxidation by intact
w xislets, and RINm5F cells 18,19 ; however, the direct
effects of IRAP on IL-1b-induced inhibition of pri-
mary b-cell function have yet to be examined. The
purpose of this study was to determine if pancreatic
b-cells express type I IL-1 receptors. We show that
IRAP inhibits IL-1b-induced nitrite formation and
iNOS expression by RINm5F cells, rat islets, and
FACS purified b-cells, and that antiserum specific
for the type I IL-1 receptor prevents IL-1b-induced
nitrite production by RINm5F cells. We also demon-
strate the expression of type I IL-1 receptors by
RINm5F cells and FACS purified pancreatic b-cells
at the level of protein and mRNA.
2. Materials and methods
2.1. Materials
Collagenase type P and dispase were from
 .Boehringer Mannheim Indianapolis, IN . Human re-
combinant IL-1b was from Cistron Pine Brook,
.  .NJ . Minimal Essential Media MEM , CMRL-1066
tissue culture media, fetal bovine serum, L-glutamine,
penicillin, and streptomycin were from Gibco Grand
.Island, NY . Human recombinant IRAP was a gener-
ous gift from The Upjohn Company Kalamazoo,
. 35  .MI . S-trans labeled methionine 1166 Cirmmol
 .was from ICN Costa Mesa, CA . Actinomycin D
 .and aminoguanidine hemisulfate AG were from
 .Sigma Chemical Co. St. Louis, MO . Rabbit anti-
iNOS antisera and hamster anti-murine type 1 IL-1
 .receptor antisera JAMA-147 were generous gifts
from Dr. Thomas Misko Monsanto Corporate Re-
.search, St. Louis, MO , and Dr. Robert Schreiber
Washington University School of Medicine, St.
.Louis, MO . EL-4 cells were from Washington Uni-
versity Tissue Culture Support Facility St. Louis,
.MO .
3. Methods
3.1. Islet isolation and b-cell purification by FACS
Islets were isolated from male Sprague-Dawley
 .rats 200–250 g; Sasco, O’Fallon, MO by collage-
w xnase digestion as described previously 20 . Islets
 .were cultured overnight 2500 isletsr2.5 ml in com-
plete CMRL1066 tissue culture medium containing
CMRL-1066; 2 mM L-glutamine, 10% heat-in-
activated fetal bovine serum, 100 unitsrml penicillin,
.and 100 mgrml streptomycin prior to the start of
experiments.
b-cells were purified from islets isolated from 12
rats. Following overnight culture islets were dis-
persed into individual cells by treatment with dispase
 . q2 q20.33 mgrml in Ca and Mg free Hanks’ solu-
w xtion 21 at 318C for 15 min. Dispersed cells were
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incubated for 45–60 min in complete CMRL-1066
media at 378C prior to FACS cell sorting. Islets were
w xpurified by FACS as described previously 10,22
using an Epics 733 cell sorter Coulter Corp., Hialeah,
.FL . FACS purification yielded a 95–98% pure b-cell
population, and an 80–85% pure population of a-cells
that contain 5–10% b-cell contamination. Purified
b-cells were cultured overnight in complete CMRL-
1066 media under an atmosphere of 95% air and 5%
CO at 378C prior to the initiation of experiments.2
3.2. Cell culture and exposure to IRAP and IL-1b
RINm5F cells were obtained from the Washington
University Tissue Culture Support Facility. The cells
were removed from T-75 flasks by treatment with
0.05% trypsin and 0.02% EDTA. The cells were
washed, counted, and plated in 96 well microtiter
plates 500 000 cellsr200 ml of complete CMRL-
.1066 , unless otherwise indicated.
RINm5F cells, islets, and purified b-cells were
preincubated for 30 min with the indicated concentra-
 . tions of IRAP. IL-1b 5 Urml was added in the
.presence of IRAP and the cells were incubated for
18–24 h under an atmosphere of 95% air and 5%
CO at 378C.2
3.3. Glucose-induced insulin secretion by islets and
FACS purified b-cells
Glucose-induced insulin secretion by isolated islets
and purified pancreatic b-cells was examined as
w xpreviously described 13 . Following incubation with
IRAP and IL-1b , islets, or b-cells were isolated by
centrifugation at 1000 rpm for 2 min in an Eppen-
.dorf 5415C microfuge and washed three times in
Krebs Ringer bicarbonate buffer KRB; 25 mM
Hepes, 115 mM NaCl, 24 mM NaHCO , 5 mM KCl,3
.1 mM MgCl , 2.5 mM CaCl , pH 7.4 containing 32 2
mM D-glucose and 0.1% BSA. FACS purified b-cells
were resuspended and aliquoted into 96-well mi-
crotiter plates 14 000 cellsr100 ml of KRB contain-
.ing 3 mM D-glucose . Insulin secretion was initiated
by the addition of an equal volume of KRB contain-
ing either 3 mM D-glucose or 37 mM D-glucose q10
mM theophylline final concentration of 20 mM glu-
.cose and 5 mM theophylline . The phosphodiesterase
inhibitor, theophylline was added because elevated
levels of cAMP are required for glucose-stimulated
w xinsulin secretion from purified b-cells 23 . Cells
were incubated for 3 h under an atmosphere of 95%
air 5% CO at 378C. After the incubation, cells were2
centrifuged at 1000 rpm for 10 min and the super-
natant was aspirated and analyzed for insulin by RIA
w x24 .
3.4. Western blot analysis
Cells were washed with 0.1 M phosphate buffered
 .saline, pH 7.4 PBS three times and lysed by the
 .addition of 25 ml of sodium dodecyl sulfate SDS
sample mix 0.25 M Tris-HCl, 20% b-mercapto-
.ethanol, 4% SDS and 15 ml dH O. Samples were2
boiled for 5 min followed by the addition of 4 ml
loading dye 0.05% bromophenol blue in 80% glyc-
.erol . Proteins were separated by 10% SDS-poly-
acrylamide gel electrophoresis and transferred to ni-
trocellulose membranes under semidry conditions.
Nitrocellulose blots were incubated overnight in
TBST 20 mM Tris, 500 mM NaCl, 0.1% Tween 20,
.pH 7.5 containing 5% nonfat dry milk. Blots were
incubated for 1.5 h at room temperature with JAMA-
 .147 1: 500 dilution in TBST containing 1% nonfat
dry milk. After incubation with primary antisera blots
were washed 3 times for 5 minrwash with TBST,
followed by a 45 min incubation at room temperature
with HRP-conjugated goat anti-hamster secondary
 .antisera 1:5000 dilution . Blots were then washed 3
times with TBST and 1 time with PBS. The IL-1 type
I receptor was detected by ECL Amersham Life
.Sciences, Arlington Heights, IL .
3.5. Immunoprecipitation of iNOS
Following overnight culture, islets or FACS puri-
fied b-cells were washed 3 times in methionine
deficient MEM 9 parts MEM without methionine: 1
.part MEM containing methionine and then cultured
in the same media 100 islets or 140,000 b-cellsr400
.ml in 24 well microtiter plates for 3 h. Islets or
b-cells were pretreated with IRAP for 30 min fol-
 .lowed by the addition of IL-1b 5 unitsrml and
 . 35actinomycin D 1 mM as indicated. S-methionine
 .300 mCi was added 5 h after the addition of IL-1b
and the cultures were incubated for an additional 13
h. Following incubation, the medium was removed
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by centrifugation and nitrite production determined
on 50 ml aliquots as described below. The cells were
washed 3 times in PBS and iNOS was immunopre-
w xcipitated using methods described previously 6,25 .
Immunoprecipitated proteins were separated on 10%
w xSDS polyacrylamide gels 26 and visualized by fluo-
rography.
3.6. RT-PCR analysis
Total RNA was isolated from FACS purified a-
and b-cells using the RNeasy RNA isolation kit from
 .Qiagen Chatsworth, CA . First strand cDNA was
prepared with 2.5 mg of total RNA from each sample
using the GIBCO-BRL Superscript preamplification
 .kit Grand Island, NY . 2.5 ml from the RT reaction
was then used in a standard 25 ml PCR reaction
containing 0.2 mM of dNTP, 50 pmol each of for-
ward and reverse primers, 2 units of Taq DNA
 .polymerase Promega, Madison, WI , 1.5 mM MgCl ,2
and 2.5 ml of the supplied 10 X reaction buffer
 .Promega . Type I IL-1 receptor and GAPDH primers
were designed according to the published sequences:
1. Type I IL-1 receptor forward primer 5X-GCTG-
GAGAGTACTCTTCATGCTG-3X reverse primer
X X 5 -GATGAATCCTGGAGTCCTTGTCC-3 PCR
.product sizes293 bp .
2. GAPDH forward primer 5X-GCTGGGGCTCAC-
CTGAAGGG-3X reverse primer 5X-GGATGAC-
X CTTGCCCACAGCC-3 PCR product sizes343
.bp .
Each PCR reaction was overlayed with one drop of
mineral oil, then incubated in a thermal cycler using
the following profile: an initial denaturation step at
948C for 5 min, followed by 30 cycles of 948C for 45
srcycle with an annealing temperature of 628C for 45
s, and a final 75 s extension at 728C. After amplifica-
tion, samples were allowed to incubate at 308C for 2
min before analyzing PCR products on a 1.5% agarose
gel stained with 0.2 mgrml ethidium bromide.
3.7. Nitrite determination
 .Culture supernatants 50 ml were mixed with 50
w xml of Griess reagent 27 , and nitrite production was
determined at an absorbance of 540 nm using a
Titertek Multiskan MCCr340 plate reader.
3.8. Statistics
Statistical comparisons were made between groups
using a one-way analysis of variance. Significant
 .differences P - 0.001 were evaluated using a
Scheffe’s F-test post hoc analysis and indicated by ).
4. Results
Treatment of rat islets with IL-1b resulted in a
 .potent inhibition of insulin secretion Fig. 1a an
 .;3-fold increase in nitrite production Table 1 . The
inhibitory effects of IL-1b on glucose-stimulated
insulin secretion by rat islets were attenuated and
completely prevented by IRAP at 0.5 mgrml and 5
mgrml, respectively. Alone, IRAP had no inhibitory
effect on glucose-stimulated insulin secretion data
.not shown . Table 1 demonstrates that IL-1b-induced
nitrite formation from the same islets used for in-
.sulin secretion studies was inhibited by IRAP in a
manner similar to the effects of IRAP on glucose-
stimulated insulin secretion. AG, a selective inhibitor
w xof the inducible isoform of NOS 15,28 , attenuated
IL-1b-induced nitrite formation, and completely pre-
Table 1
Effects of IRAP on IL-1-induced nitrite formation by islets and
FACS purified b-cells





5 mgrml IRAP 12.1"0.6 5.96"0.7
)IL-1q0.05 mgrml IRAP 41.8"0.5 –
))IL-1q0.5 mgrml IRAP 18.7"0.9 6.83"1.9
))IL-1q5.0 mgrml IRAP 13.5"0.3 5.96"1.5
))IL-1q0.5 mM AG 21.4"0.8 8.12"1.5
Nitrite production by rat islets and FACS purified b-cells was
determined on the culture medium following a 24 h incubation
with the indicated cytokines as stated in Section 2. Results are the
average"SEM of three individual experiments containing three
 .replicates per condition islets and one experiment containing
three replicates per condition, that is representative of three
 .individual experiments FACS purified b-cells . Statistically sig-
nificant nitrite formation and inhibition of nitrite production are
indicated by ) and )), respectively
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Fig. 1. Effects of IRAP on IL-1b-induced inhibition of insulin
 .secretion by rat islets and FACS purified b-cells. Islets a or
 .FACS purified b-cells b were pretreated with the indicated
 .concentrations of IRAP for 30 min, IL-1b 5.0 Urml and AG
 .0.5 mM were then added and the islets or b-cells were incu-
bated for 18 or 24 h, respectively. The islets or b-cells were
isolated and then glucose-induced insulin secretion was examined
as described in Section 2. Results are the average"SEM of three
individual experiments containing three replicates per condition
 .islets and average"SEM of an individual experiment contain-
ing three replicates per condition, that is representative of three
 .individual experiments FACS purified b-cells . Statistically sig-
nificant inhibition of glucose-stimulated insulin secretion and
preventative effects of IRAP on IL-1b-induced inhibition of
glucose-stimulated insulin secretion are indicated by ) and )),
respectively.
vented the inhibitory effects of IL-1b on glucose-
stimulated insulin secretion by islets.
IRAP also prevented IL-1b-induced nitrite forma-
 .tion Table 1 and IL-1b-induced inhibition of glu-
 .cose-stimulated insulin secretion Fig. 1b by FACS
purified b-cells, in a manner similar to its effects on
rat islets. At 0.5 mgrml and 5 mgrml, IRAP nearly
completely and completely prevented the inhibitory
effects of IL-1b on glucose-stimulated insulin secre-
 .tion from FACS purified b-cells Fig. 1b . Also, AG
attenuated the inhibitory effects of IL-1b on insulin
secretion and completely prevented IL-1b-induced
nitrite formation from FACS purified b-cells Table
.1 . As shown by immunoprecipitation in Fig. 2,
IL-1b induced the expression of iNOS in islets and
purified pancreatic b-cells. IRAP, at 5 mgrml, com-
pletely prevented IL-1b-induced iNOS expression by
islets and FACS purified b-cells. In addition, the
 .transcriptional inhibitor actinomycin D lane 4 also
prevented the expression of iNOS by IL-1b treated
islets.
These findings indicate that antagonism of the IL-1
receptor prevents IL-1-induced iNOS expression by
islets and purified b-cells. To provide additional
support for the expression of type I IL-1 receptors by
pancreatic b-cells, antiserum specific for the type I
w xIL-1 receptor, JAMA-147, 29 was used to neutralize
IL-1b-induced nitrite formation by RINm5F cells
 .Fig. 3 . In a concentration-dependent manner,
Fig. 2. Effects of IRAP on IL-1b induced iNOS expression by
rat islets and FACS purified b-cells. Islets or FACS purified
b-cells were pretreated with 5 mgrml of IRAP for 30 min lanes
.  .3 , and then exposed to 5 Urml IL-1b lanes 2–4 , and 1 mM
 . 35actinomycin D lane 4 for 5 h. 300 mCi of S-methionine was
added and the islets or b-cells were incubated an additional 13 h.
Immunoprecipitated proteins were separated on a 10% SDS
polyacrylamide gel and visualized by fluorography. Results are
representative of two individual experiments.
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Fig. 3. Effects of JAMA-147 on IL-1-induced nitrite formation
by RINm5F cells. RINm5F cells 100000r200 ml of complete
.CMRL-1066 were preincubated for 30 min with the indicated
 .concentrations of JAMA-147. IL-1b 0.5 unitsrml was then
added and the RINm5F cells were cultured for an additional 18 h.
The supernatant was removed and nitrite production was deter-
mined. The results are expressed as % of control with control
being the level of nitrite stimulated by IL-1. Results are the
mean"SEM of five independent experiments containing 3 repli-
catesrcondition.
JAMA-147 prevented IL-1b-induced nitrite forma-
tion with half-maximal inhibition at 5 mg and com-
 .plete inhibition at 10 mg Fig. 3 . Irrelevant hamster
antiserum does not inhibit IL-1-induced iNOS ex-
 .pression by RINm5F cells data not shown .
To confirm that b-cells express type I IL-1 recep-
tors, we have examined receptor expression by west-
ern blot analysis, shown in Fig. 4. JAMA-147 cross
Fig. 4. Western Blot Analysis of Type 1 IL-1- Receptor. The
expression of type 1 IL-1 receptor was evaluated by western blot
 . analysis of RINm5F cells 0.5 mgrlane and EL-4 cells 0.45
.mgrlane protein lysate was separated on 10% SDS-PAGE gel as
stated in Section 2. Results are representative of three individual
experiments.
Fig. 5. Detection of type 1 IL-1 receptor mRNA expression by
primary a- and b-cells purified by FACS. Type 1 IL-1 receptor
and GAPDH mRNA expression by FACS purified a- and b-cells
was evaluated by RT-PCR as stated in Section 2. For PCR
amplification 1, 1r3, or 1r9 ml of template cDNA was used for
the indicated PCR reactions. The predicted size of the type 1 IL-1
receptor product is 293 bp and GAPDH product of 348 bp.
Results are representative of two individual experiments.
reacted with a 60 kDa protein in both RINm5F and
EL-4 cells. EL-4 cells express high levels of type I
 .IL-1 receptor 10 000rcell and have been used as a
positive control in this experiment. RT-PCR was also
employed to confirm the expression of the type I IL-1
receptor by FACS purified b-cells. Expression of the
type I IL-1 receptor was detectable in mRNA isolated
from a- and b-cells purified by FACS. However, as
shown in Fig. 5, reducing the amount of template
cDNA for the PCR reaction by 1r3 or 1r9 resulted
in loss of detectable type I IL-1 receptor mRNA in
FACS purified a-cells. Under these conditions, IL-1
type I receptor mRNA was still detectable in RNA
isolated from FACS purified b-cells.
5. Discussion
In this report we demonstrate that IRAP can inhibit
IL-1b-induced signal transduction events that lead to
the expression of iNOS and the production of nitric
oxide by FACS purified pancreatic b-cells. A 2000-
fold molar excess of IRAP prevents IL-1-induced
 .expression of iNOS Fig. 2 and the inhibitory effects
of IL-1b on glucose-stimulated insulin secretion by
 .rat islets and FACS purified b-cells Fig. 1 . These
findings are consistent with the results of Eizirik et
w xal. 18,19 who have shown that a 1000–10 000-fold
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excess of IRAP over IL-1b , prevents both the stimu-
latory and inhibitory effects of IL-1b on insulin
secretion by islets and provides further relevance that
NO mediates the inhibitory effects of IL-1b on
b-cell function. Concentrations of IRAP required to
block IL-1-induced signaling range from equimolar
to 10,000X fold excess, and depend on both the cell
w xtype and response generated 30,31 . This wide range
of concentrations is believed to be due to IL-1 recep-
tor subtypes, the type I signaling receptor and the
w xtype II decoy receptor 31,32 . IRAP binds equally
well to both receptor subtypes of the IL-1 receptor
 w x.type I and type II; 31,32 ; therefore, our present
findings cannot distinguish if IRAP is binding to the
type I, type II, or both IL-1 receptors. However,
antiserum specific for the type I IL-1 receptor
 .JAMA-147 neutralizes IL-1b-induced NO produc-
tion by RINm5F cells and also recognizes a single
 .protein by western blot analysis Fig. 4 . The appar-
ent molecular weight of the JAMA-147 cross-reactive
protein is somewhat lower than expected 60 vs. 80
.kDa . The 80 kDa species is believed to be a heavily
glycosylated form of the type I IL-1 receptor, and the
60 kDa is believed to be a non-glycosylated form
w x33 . Our data supports the presence of a non-glyco-
sylated form of the type I IL-1 receptor in RINm5F
cells. The lack of an 80 kDa species may reflect a
low level of surface expression of glycosylated IL-1
receptor. It has been estimated that pancreatic b-cells
w xexpress as few as 50–100 receptorsrcell 5 .
Many cell types express both the type I and type II
w xIL-1 receptors 34 . IL-1 binding studies on the ham-
ster insulinoma cell line HIT-T15 indicate the pres-
ence of both high and low affinity binding sites
which may correspond to type I and II IL-1 receptors
w x5 . Recently the presence of both type I and type II
IL-1 receptor mRNA has been demonstrated in HIT-
w xT15 cells 35 , further suggesting the presence of both
receptor types on primary b-cells. In situ hybridiza-
tion of mouse pancreatic tissue also indicates the
presence of type I IL-1 receptor mRNA within islets
w x36 ; however, the cellular source of this mRNA is
unknown. By RT-PCR we show that FACS purified
b-cells express type I IL-1 receptor mRNA, and the
a-cells do not appear to express this receptor. The
detection of low levels of IL-1 type I receptor mRNA
in a-cells is believed to be a result of b-cell contami-
 .nation of the a-cell preparation Fig. 5 . FACS pu-
rification of islet cells results in a 95–98% pure
population of b-cells and an 80–85% pure popula-
tion of a-cells, with the purified a-cells containing
5–10% b-cell contamination. Also, we have shown
previously that a-cells do not express iNOS or pro-
duce NO in response to IL-1b. These results suggest
that a-cells may not express the IL-1 type I signaling
w xreceptors 6,10 . These findings indicate at a func-
tional, protein, and mRNA level, the presence of IL-1
receptors on pancreatic b-cells, the cell type selec-
tively destroyed during the development of autoim-
mune diabetes.
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